GCSF Adjunct Therapy for Biliary Atresia

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 15, 2018

Primary Completion Date

January 31, 2020

Study Completion Date

January 31, 2020

Conditions
Biliary Atresia
Interventions
DRUG

Granulocyte Colony-Stimulating Factor

G-CSF is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells. Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology with NEUPOGEN® as the Amgen Inc. trademark for filgrastim. G-CSF regulates the production, proliferation and differentiation of neutrophils and hematopoietic stem cell precursors within the bone marrow leading to dose-dependent increase in circulating neutrophils and hematopoietic stem cells in the blood. It is indicated to reduce the incidence of infection in patients with severe neutropenia, for neutrophil recovery in neutropenic patients with bone marrow depletion, to mobilize hematopoietic progenitor stem cell for collection by leukapheresis in hematopoietic stem cell transplantation.

Trial Locations (2)

20010

Children's National Medical Center, Washington D.C.

Unknown

National Childrens Hospital, Hanoi

All Listed Sponsors
collaborator

T. Rose Clinical, Inc., United States

UNKNOWN

collaborator

Children's National Research Institute

OTHER

collaborator

Big Leap Research

OTHER

lead

Holterman, Ai-Xuan, M.D.

INDIV